Evaluating the accuracy of three international guidelines in identifying the risk of malignancy in pancreatic cysts: a retrospective analysis of a surgical treated population.

Background and study aims The international consensus Fukuoka guideline (Fukuoka ICG), The European evidence-based guideline on pancreatic cystic neoplasms (European EBG) and the American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts (AGA IG) are 3 frequently cited guidelines for the risk stratification of neoplastic pancreatic cysts. The aim of this study was to assess the accuracy of detecting malignant cysts by strictly applying these guidelines retrospectively to a cohort of surgically resected pancreatic cysts. Patients and methods 72 resected cysts were included in the analysis. Invasive carcinoma, high grade dysplasia and neuro-endocrine tumour were considered as "malignant cysts" for the purpose of the study. Results 32% of the resected cysts were malignant. The analysis showed that the Fukuoka ICG, European EBG and AGA IG had a sensitivity of 66,8%, 95,5%, 80%; a specificity of 26,8%, 11,3%, 43,8%; a positive predictive value of 31,8%, 35%, 47,1% and a negative predicted value of 61,1%, 83,3%, 77,8% respectively. The missed malignancy rate was respectively 11,3%, 1,5%, 7,7% and surgical overtreatment was respectively 48,4%, 59,1%, 34,6%. Conclusion In this retrospective analysis, the European EBG had the lowest rate of missed malignancy at the expense of a high number of "unnecessary" resections. The Fukuoka ICG had the highest number of missed malignancy. The AGA IG showed the lowest rate of unnecessary surgery at the cost of a high number of missed malignancy. There is need to develop better biomarkers to predict the risk of malignancy.

[1]  T. Okumura,et al.  Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. , 2019, Gastroenterology.

[2]  C. Bassi,et al.  Importance of main pancreatic duct dilatation in IPMN undergoing surveillance , 2018, The British journal of surgery.

[3]  J. V. van Hooft,et al.  Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines , 2018, Visceral Medicine.

[4]  F. Real,et al.  European evidence-based guidelines on pancreatic cystic neoplasms , 2018 .

[5]  R. Salem,et al.  Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms , 2017, Medicine.

[6]  Jin‐Young Jang,et al.  of the pancreas , 2017 .

[7]  J. Barkin,et al.  Pancreatic Cysts: Controversies, Advances, Diagnoses, and Therapies , 2017, Pancreas.

[8]  J. Farrell.  Pancreatic Cysts and Guidelines , 2017, Digestive Diseases and Sciences.

[9]  P. Fockens,et al.  Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. , 2017, Gastrointestinal endoscopy.

[10]  G. Ginsberg,et al.  Comparing American Gastroenterological Association Pancreatic Cyst Management Guidelines with Fukuoka Consensus Guidelines as Predictors of Advanced Neoplasia in Patients with Suspected Pancreatic Cystic Neoplasms. , 2016, Journal of the American College of Surgeons.

[11]  H. Reber,et al.  Pancreatic Cyst Disease: A Review. , 2016, JAMA.

[12]  Jin-Young Jang,et al.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts. , 2015, Gastroenterology.

[13]  P. Moayyedi,et al.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. , 2015, Gastroenterology.

[14]  H. Friess,et al.  European experts consensus statement on cystic tumours of the pancreas. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.